![]() | |
Clinical data | |
---|---|
Drug class | Monoamine oxidase B (MAO-B)inhibitor |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C15H15F3N2O3S |
Molar mass | 360.35 g·mol−1 |
3D model (JSmol) | |
| |
|
Adarigiline (INNTooltip International Nonproprietary Name) is amonoamine oxidase inhibitor (MAOI) that was never marketed.[1][2][3][4] It is specifically amonoamine oxidase B (MAO-B)inhibitor.[1][2][3] This drug candidate was first described in 2009, in apatent assigned to Helicon Therapeutics.[5]
tadarigilinum adarigiline (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)- 1,2-oxazol-3-yl]thiophen-2-yl}methanone monoamine oxidase B inhibitor [...] C15H15F3N2O3S 1124197-79-0
adarigilinum adarigiline (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)- 1,2-oxazol-3-yl]thiophen-2-yl}methanone [...] C15H15F3N2O3S
![]() | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |